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ABSTRACT
Objectives: To evaluate the quantitative effects of the
drug price reduction on pharmaceutical expenditures
and the new guidelines to restrict prescribing on drug
utilisation for antihypertensive drugs.
Design: We used an interrupted time series design
with the National patient sample data of Health
Insurance Review and Assessment Service in South
Korea.
Methods: 54 295 participants who were with primary
hypertension from the National patient sample data of
Health Insurance Review and Assessment Service were
included. The study period was from March 2011 to
December 2013. The dependent variables were
antihypertensive drug costs, antihypertensive drug cost
per prescribing day, daily drug utilisation, average
number of drugs per month, percentage of original
drugs per prescription, drug overutilisation and
prohibited combinations. Segmented regression
analysis was used.
Results: The drug price reduction reduced
expenditure (US$−1.51, −10.2%), and the new
guidelines reduced expenditures even more (US$
−2.13; −16.2%). These policies saved US$4.22 (28%)
of antihypertensive drug costs per patient in December
2013 compared to March 2012. Drug price reduction
policy was introduced in April 2012. We established
the policy effect by comparing it before (March 2012)
with after(21 months later-December 2012). The
effects of the guidelines decreased expenditures, daily
drug utilisation and the average number of drugs per
month more than did the drug price reduction.
Conclusions: Both policies saved money. The
guidelines were more effective over time and had fewer
side effects such as increasing daily drug utilisation
and number of drugs than the effects of drug price
reduction.
INTRODUCTION
The increasing pharmaceutical expenditures
are the one of the biggest healthcare issues in
Korea. The average annual pharmaceutical
expenditure per capita kept increasing
from 2000 to 2011. The increasing rate was
9.8% from 2000 to 2009, and 5.4% from 2009
to 2011. These rates were higher than for
most of the Organisation for Economic
Co-operation and Development (OECD)
countries.1 As a result, expenditure on phar-
maceuticals in Korea was 21.3% of total
healthcare expenditure in 2011 versus an
average rate of 16.4% among OECD
countries’.
Recently, the Korean government intro-
duced several pharmaceutical policies to
limit the increases in pharmaceutical expen-
ditures as well as seeking to improve the
quality of care.2 This included policies
around the pricing system and guidelines
for the management of patients with hyper-
tension. One policy is that the Korean gov-
ernment reformed the drug pricing system
and reduced the prices of existing drugs by
Strengths and limitations of this study
▪ In this study, it is possible to compare the
effects of two drug policies for expenditures, the
drug price reduction and the new guideline,
which is prescribing restrictions, with national
representative data.
▪ The reduction of expenditures by the drug price
reduction was greater than the new guidelines at
the policy initiation.
▪ The new guidelines had less side effects such as
increasing daily drug utilisation and number of
drugs than the drug price reduction, which is a
direct price control.
▪ The 9-month overall effect of the new guidelines
reduced expenditures and some drug utilisation
variables more effectively than did the drug price
reduction.
▪ This study identified only for drug utilisation and
pharmaceutical expenditures. The health out-
comes were not evaluated in this study.
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rules of the reformed drug pricing system in April 2012.
The other relates to the guidelines which are the pre-
scribing restrictions for antihypertensive drugs in
January 2013.3
The previous system priced each drug according to its
order of registration. For example when pricing generic
drugs after patent expirations, the later a generic drug
was registered, the lower was its price (see online supple-
mentary ﬁle 1).4 The Korean government introduced a
new pricing system to improve the previous pricing
system. Its goals are as follows: to reduce pharmaceutical
expenditures, increase accessibility of drugs, decrease the
burden of health insurance premiums, block companies’
rebate activities5 and improve competitiveness among
Korean pharmaceutical companies.6 This reform was
applied to 13 184 listed drugs on the positive list. Prices
for 6504 drugs were reduced, which led to a 14.2% reduc-
tion in the price of listed drugs (ﬁgure 1).7 8
Hypertension is the most prevalent chronic disease in
Korea, with 29% of individuals aged over 30 years
affected in 2012.9 One previous research reported that
the primary physician’s blood pressure control was poor
in Korea.10 The Korean government introduced guide-
lines for antihypertensive drugs. It was developed to
restrict prescribing and was focused on prescription and
reimbursement to control drugs overutilisation and
improper prescriptions. The Korean government exam-
ined research papers and other guidelines to deﬁne the
proper prescription of 1112 antihypertensive drugs (box
1).8 There are penalties for physicians who do not
follow the guidelines. The Korean national health
insurer does not reimburse the excess over the guide-
lines. This penalty lowers the healthcare provider’s evalu-
ation scores which decide monetary incentives.
If physicians do not follow the guidelines, they have to
pay a penalty and the government does not pay the
excess portion.
The drug price reduction and the new guidelines are
different; the drug price reduction is a kind of direct
price control policy and the new guidelines is a pre-
scribing restriction policy on utilisation. The objectives
of this study are to evaluate the quantitative effects of
the drug price reduction and the new guidelines on
the drug price reduction and pharmaceutical
expenditures.
Backgrounds in Korea
The Korean National Health Insurance system achieved
universal coverage for the population in 1989.11 There
are two types of insurance: health insurance and
Medical aid. Medical aid is a type of health insurance
for low-income people, like Medicaid in the USA.12
There are 1.61 million Medical aid beneﬁciaries, equiva-
lent to 3.2% of the population of Korea in 2011.9 Type 1
Medical Aid beneﬁciaries can use free inpatient services,
and outpatient services with a $1–$3 copayment. Type 2
Medical aid beneﬁciaries must make a copayment of
10% of inpatient medical costs, 15% of medical costs for
hospital-based outpatient services, approximately $2 for
clinic-based outpatient services and approximately $1 for
drug costs. Health insurance beneﬁciaries copay 30% of
drug costs.
The most of payments made under the Korean reim-
bursement system is the regulated fee-for-service
payment. A diagnosis-related group payment method is
used for seven diseases.13 To manage payments for
drugs, Korea implemented the positive list system.2
METHODS
Data and study population
This study used the National Patient Sample (NPS) data
for hypertension from Health Insurance Review and
Assessment Service reimbursement data. In this data,
prescription data for antihypertensive drugs were
included. The study period was from March 2011 to
December 2013. The sample included 57 150 partici-
pants, which were 1% of the randomly sampled, anon-
ymised hypertensive patients from national hypertensive
patients. Only patients with primary hypertension were
included. A total of 54 295 participants were included in
this study. Data from January and February 2011 were
excluded because of missing drug utilisation data. In
this analysis, the guidelines began in February 2013, as
there was a 1-month lagged effect after implementation
of the new guidelines.
Dependent variables
Dependent variables were classiﬁed into two categories:
drug utilisation and pharmaceutical expenditures.
For drug utilisation, daily drug utilisation, average
number of drugs per month, percentage of original
drugs per prescription, drug overutilisation and prohib-
ited combinations were included in the analysis. Daily
drug utilisation represented how many participants took
antihypertensive drugs per day. Daily dosage was adjusted
by DDD. DDD indicates daily dose, which is deﬁned by
the WHO.14 A (daily drug utilisation=1) indicated that
the daily dosage was equal to DDD. If daily drug utilisa-
tion was over one, participants took overdoses of their
drugs more than the DDD. The percentage of original
drugs per prescription was calculated as (the number of
original antihypertensive drugs/the number of all antihy-
pertensive drugs)×100. The drug overutilisation and pro-
hibited combination variables were binary. The number
of drug overutilisations indicates how physicians violated
the guidelines by prescribing more than two agents per
ingredient. It is restricted by the new guideline; for
example, two β-blockers cannot be prescribed at at one
outpatient visit. The number of prohibited combinations
indicates how physicians violated the prohibited combi-
nations clause in the guideline, such as diuretic+α
blocker (box 1). Antihypertensive drug costs per month
and antihypertensive drug cost per prescribing day were
included. An exchange rate of 1000 KRW is around US
$1.
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Independent variables
Age, sex, region, insurance type, Charlson comorbidity
index (CCI) and combinations of antihypertensive agents
were included as covariates. Age was classiﬁed into four
groups: under 49, 50–59, 60–69, over 70 years. Region of
medical facilities which a patient visited was categorised
into Seoul, metropolitan and rural. There were two insur-
ance types: health insurance and medical aid. CCI was
calculated yearly based on Quan’s methods.15 Nineteen
diseases were classiﬁed into scores of 1, 2, 3 and 6.16 The
CCI per subject was calculated from the sum of all scores.
In this study, CCI was grouped as scores of 0, 1, 2 and
over 3. Combinations of antihypertensive agents repre-
sented the number of kinds of antihypertensive drugs
that participants took monthly. Combinations of antihy-
pertensive agents are used to adjust the severity of the
hypertension, for instance, in cases of resistant hyperten-
sion.17 These were classiﬁed as 0, 1, 2 and over 3.
A subgroup analysis for insurance type was conducted
because Medical aid beneﬁciaries usually overuse health-
care services in Korea.18
Statistical methods
Segmented regression analysis of interrupted time series
design was used to assess policy effects with the methods
in Wagner et al19 and Sen et al20 Our segmented regres-
sion analysis equation was in Equation 1:
Yit ¼ b0 þ b1  timet þ b2  new pricing systemtþ
b3  time after new pricing systemt þ b4
 new guidelinetþ
b5  time after new guidelinet þ b6  seasont
þ Xit þ eit
ð1Þ
Y: dependent variables; i: each patient; t: time period;
time: a continuous variable started in January 2011; drug
price reduction: a binary variable (0 before January
2012; 1 after April 2012); time after drug price reduction:
a continuous variable started in April 2012; new guide-
line: a binary variable (0 before January 2013; 1 after
February 2013); time after new guideline: a continuous
variable started in February 2013; season: seasonality
(spring, summer, fall, winter); X: independent variables;
e: the error term; New guidelines and time after new
guidelines were started in February 2013 because there
Figure 1 Estimated drug prices
after policy change (after April
2012).8
Box 1 Prescription and reimbursement guideline for
hypertensive drugs8
Antihypertensive drugs administered to hypertensive patients
without comorbidity are allowed under the following conditions
and reimbursement is provided if the conditions below are met.
Prescription and reimbursement guidelines for antihypertensive
drugs
A. Time for administering drugs.
1. If systolic blood pressure is over 140 mm Hg or diastolic blood
pressure is over 90 mm Hg, administration of drugs is allowed.
2. Patients without risk factors for cardiovascular disorders
should be advised to improve lifestyle first.
B. Rules for drug administration.
1. Only one antihypertensive agent should be administered
first. If systolic blood pressure is over 160 mm Hg or dia-
stolic blood pressure is over 100 mm Hg, two more antihy-
pertensive agents can be administered instead of one
antihypertensive agent.
2. Even after antihypertensive agents have been administered, if
systolic blood pressure is over 140 mm Hg or diastolic blood
pressure is over 90 mm Hg, various kinds of antihypertensive
agents can be administered. If you use four or more different
types of drugs, a written statement justifying the prescription
is necessary.
3. The following combinations are not recommended. If you do
decide to use them, only cases for which a valid reason is
provided are allowed.
a. Diuretic+α blocker
b. β blocker+ACE inhibitor
c. β blocker+angiotensin II receptor antagonist
d. ACE inhibitor+angiotensin II receptor antagonist
4. Drugs consisting of the same ingredients are administered once.
The administration of compounds is considered to be the same
as administering drugs that are components of the compounds.
Target patients: Hypertension patients without comorbidity, as
follows.
▸ Cardiovascular diseases: angina pectoris, myocardial infarc-
tion, left ventricular hypertrophy, heart failure, ischaemic
heart diseases
▸ Cerebrovascular diseases, chronic kidney diseases (includ-
ing proteinuria), diabetes, peripheral blood vessel diseases.
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was a 1-month lagged effect of the new guideline. As
there is the possibility of seasonal variation in blood pres-
sure, seasonality was included in the equation.21
For this segmented regression analysis, each subject’s
data were aggregated monthly. The unit of analysis is a
‘person-month’. Generalised estimation equation (GEE)
was conducted using proc genmod in SAS 9.3 with link
identity, distribution normal and AR (1). For binary vari-
ables, such as drug overutilisation and prohibited combi-
nations, a probit model was used in GEE.
Calculating marginal effects of policies
As the interpretation of segmented regression analysis is
difﬁcult because there are many variables related to
time, marginal effects on dependent variables were cal-
culated to display exact effects of policies. β2 and β3 were
related to the drug price reduction policy. Marginal
effects of only the drug price reduction in December
2012 compared to March 2012 can be calculated as
(β2+β3×9). Similarly, the marginal effects of the new
guidelines in October 2013 compared to January 2013
can be calculated as (β4+β5×9). The marginal effects of
both policies in December 2013 compared to March
2012 can be calculated as (β2+β3×21+β4+β5×11).
The coefﬁcient estimates of drug overutilisation and
prohibited combinations were calculated in the probit
model, as they were needed to transform to marginal
effects at the sample means of variables for interpret-
ation. They were calculated with the margins command
in Stata V.13. For example, they can be interpreted as
increasing probability by amount of β5 per unit increase.
RESULTS
Table 1 shows the general participant characteristics in
this study. A total of 54 295 participants were included
and the highest proportion was in the over 70 years age
group at 15 428. There were 24 842 (45.8%) men and
29 453 (54.3%) women. Most of the participants had
health insurance (93.8%). More than half lived in rural
areas (53.6%). Combinations of hypertensive agents
were scored as 0, 1, 2 and over 3, with 14 000 (6.2%),
14 571 (26.8%), 10 628 (19.6%) and 15 096 (27.8%)
participants.
The monthly trends of dependent variables are dis-
played in ﬁgures 2–4. We did not show the trends for all
study populations because they are similar to the trends
of the health insurance population which made up most
of this study population (93.8%).
Daily drug utilisation and number of drugs showed a
decreasing trend after the guidelines. They were not
affected by the drug price reduction. Number of drugs,
number of drug overutilisations, and number of prohib-
ited combinations showed decreasing trends after the
new guidelines were implemented. The overall utilisa-
tion of originators did not change after the introduction
of the new policies’(ﬁgures 2, and 3). The expenditures
remarkably decreased in April 2012 and February 2013
for health insurance participants. For Medical aid parti-
cipants, the expenditures decreased in April 2012
(ﬁgure 4).
The trend of daily drug utilisation increased signiﬁ-
cantly after the drug price reduction, and decreased
after the guidelines were implemented. The average
number of drugs per month showed an increasing trend
after the drug price reduction, but it decreased after the
new guidelines. Only the baseline time variable was sig-
niﬁcant for per cent of original drugs (table 2).
Table 3 shows the results of the segmented regression
analysis for expenditures. For expenditures, the effects
of the drug price reduction at the time when the policy
was implemented were bigger than those of the new
guidelines. However, the effects of the new guidelines
were bigger than those of the drug price reduction for
the trends after the policy was implemented.
The probabilities of drug overutilisation and prohib-
ited combination showed a signiﬁcant upward trend
after the drug price reduction, but they showed a down-
ward trend after the new guidelines (table 4).
Marginal effects for the dependent variables are pre-
sented in table 5. Antihypertensive drug costs decreased
by 4.2217 (26%) USD in December 2013 as a result of
both policies. The effects of the guidelines decreased
expenditures, daily drug utilisation and average number
of drugs per month more than did the drug price
reduction.
Table 1 General characteristics of study participants at
baseline (March 2011)
N (%)
Age (years)
−49 8982 16.5
50–59 14 975 27.6
60–69 14 910 27.5
70− 15 428 28.4
Sex
Woman 29 453 54.3
Man 24 842 45.8
Region
Seoul 11 831 21.8
Metropolitan 13 356 24.6
Rural 29 108 53.6
Insurance type
Health insurance 50 942 93.8
Medical aid 3353 6.2
Charlson comorbidity index
0 14 000 25.8
1 14 571 26.8
2 10 628 19.6
3− 15 096 27.8
Combinations of hypertensive agents
0 3295 6.1
1 32 219 59.3
2 14 183 26.1
3− 4598 8.5
Total 54 295 100.0
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DISCUSSION
In this study, we identiﬁed the policy effects of the drug
price reduction and guidelines, which prescribe restric-
tion, on the utilisation and expenditures of antihyper-
tensive drugs.
We used the segmented regression analysis to classify
the effects of policies. Segmented regression analysis of
interrupted time series analysis is a useful method to
evaluate policy evaluation.19 It can compare the time
series pattern before the intervention with the pattern
after the intervention. As systematic changes can occur
over time, this analysis is frequently used to measure the
degree of change in the use of medical care.19 20 22–25
Most studies using segmented analysis were analysed
with time-aggregated data without considering the per-
sonal level. Sen et al’s20 study used segmented regression
analysis with data aggregated into “person-months.” This
study was conducted based on Sen et al’s method, and
thus it was able to overcome the limitation mentioned
by most studies regarding an unadjusted case-mix. This
study employed the GEE model. Model selection
between GEE or the mixed model is a matter of
debate.26 The strength of GEE is that it is a very ﬂexible
approach to analyse correlated data from the same parti-
cipants over time.27 28 The limitation of the mixed
model is the assumption of residual normality.26 29 Thus,
the study results were interpreted based on GEE.
For daily drug utilisation results, the baseline time of
the effect on daily drug utilisation showed a decreasing
trend. This may have been the effect of recommending
low doses and multiple antihypertensive combina-
tions.30 31 However, daily drug utilisation increased after
Figure 2 Trends of monthly
drug utilisation per patient.
(A) Daily drug utilisation; (B)
Average number of drugs; (C) Per
cent of original drugs.
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the guidelines were implemented. There were no
dosage clauses in the guideline; only clauses for blood
pressure conditions and drug combinations are
included. This may have led to an increase in the quan-
tity of drugs used per day. However, it changed to a
downward trend after the guideline.
At the start of policy implementation, the reduction of
expenditures owing to drug price reductions was greater
than the impact of the new guidelines. However, over a
9-month period, the new guidelines reduced expendi-
tures and some drug utilization variables more effect-
ively than did the drug price reduction in the
segmented regression analysis. This may be because
healthcare providers may substitute the drugs whose
prices were not reduced and increase utilisation after
introduction of the drug price reduction. Thus, the
Figure 3 Trends of monthly per
cent of drug overutilisation and
prohibited combination per patient
(A) drug overutilisation; (B)
prohibited combination.
Figure 4 Trends of monthly
expenditures per patient.
(A) Antihypertensive drug costs;
(B) Antihypertensive drug cost
per prescribing day.
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Table 2 Results of the segmented regression analysis for drug utilisation*
Time
Drug price
reduction
Time after drug
price reduction New guideline
Time after new
guideline
Group Estimate p Value Estimate p Value Estimate p Value Estimate p Value Estimate p Value
Daily drug utilisation All −0.0016 <0.001 0.0018 0.225 0.0015 <0.001 0.0035 0.026 −0.0038 <0.001
Health insurance −0.0016 <0.001 0.0022 0.143 0.0015 <0.001 0.0027 0.104 −0.0037 <0.001
Medical aid −0.0014 0.147 −0.0040 0.628 0.0007 0.689 0.0181 0.006 −0.0062 0.002
Average number of drugs per month All 0.0047 <0.001 −0.0265 <0.001 0.0016 <0.001 −0.0073 0.004 −0.0171 <0.001
Health insurance 0.0048 <0.001 −0.0263 <0.001 0.0016 <0.001 −0.0100 <0.001 −0.0169 <0.001
Medical aid 0.0035 0.007 −0.0332 0.003 0.0012 0.566 0.0352 <0.001 −0.0204 <0.001
Per cent of original drugs (%) All −0.0958 <0.001 −0.0457 0.557 0.0156 0.454 0.0460 0.535 0.0193 0.373
Health insurance −0.0971 <0.001 −0.0416 0.603 0.0211 0.322 0.0548 0.476 0.0064 0.774
Medical aid −0.1001 0.098 −0.0657 0.849 −0.0470 0.637 −0.1195 0.679 0.1951 0.091
*All results were adjusted by age, sex, region, insurance type, Charlson comorbidity index and combinations of hypertension agents.
Table 3 Results of the segmented regression analysis for expenditure*
Time
Drug price
reduction
Time after drug
price reduction New guideline
Time after new
guideline
Group Estimate p Value Estimate p Value Estimate p Value Estimate p Value Estimate p Value
Antihypertensive drug costs (USD) All 0.0839 <0.001 −1.3796 <0.001 −0.0149 0.048 −0.3182 <0.001 −0.2010 <0.001
Health
insurance
0.0858 <0.001 −1.3828 <0.001 −0.0164 0.033 −0.3524 <0.001 −0.1956 <0.001
Medical aid 0.0532 0.015 −1.3792 <0.001 0.0142 0.679 0.2265 0.199 −0.2901 <0.001
Antihypertensive drug cost per prescribing
day (USD)
All 0.0021 <0.001 −0.0424 <0.001 −0.0002 0.443 −0.0066 <0.001 −0.0074 <0.001
Health
insurance
0.0022 <0.001 −0.0423 <0.001 −0.0003 0.298 −0.0074 <0.001 −0.0073 <0.001
Medical aid 0.0009 0.182 −0.0453 <0.001 0.0011 0.318 0.0055 0.258 −0.0094 <0.001
*All results were adjusted by age, sex, region, insurance type, Charlson comorbidity index and combinations of hypertension agents.
Yoo
K-B,etal.BM
J
Open
2015;5:e006940.doi:10.1136/bm
jopen-2014-006940
7
O
p
e
n
A
c
c
e
s
s
effectiveness of the guidelines improved over time due
to the reduction of drug utilisation. Drug price reduc-
tion is a direct price control policy, and the new guide-
lines may be described as a prescribing restriction. A
direct price control policy is typically effective to
decrease expenditures.32 However, some empirical
studies reported that it was difﬁcult to control costs,33–35
because companies have sought ways to increase sales
volumes of drugs that have not been affected by the
drug price reduction. On the other hand, drug price
control policies linked to extensive demand-side initia-
tives, including education, ﬁnancial incentives and
switching polices, can reduce expenditures even though
volumes increase.36 Therefore, there is a need to iden-
tify policy effects of drug price control policy on utilisa-
tion of drugs which have been not affected by policy.
The unintended impact of this study was that the
drug price reduction increased the average number of
drugs per month and drug overutilisation and prohib-
ited combination. However, the unintended impacts of
the guidelines were unclear. The unintended impacts
of restriction policies on the prescription of drugs were
not clearly identiﬁed, except that they potentially
reduced access to certain drugs, including patented
drugs within a class when generics were available.37–41
The guidelines changed physicians’ behaviour such that
the new guidelines resulted in desirable trends, because
the guidelines covered all antihypertensive drugs.
Drug overutilisation and prohibited combinations
increased after the drug price reduction and decreased
after the new guidelines. They are related to the effects of
the number of types of antihypertensive drugs per
month. In the report of the Ministry of Health and
Welfare in Korea,42 the lower the price reduction rate, the
more was the increase in drug utilisation. The utilisation
of drugs, which was not affected by the drug price reduc-
tion, increased by 12.3%. Most of the combinations for
the treatment of hypertension were not affected by the
policy. The trend of recommending multiple antihyper-
tensive combinations and the policy effect caused increas-
ing drug overutilisation and prohibited combinations.31
Price regulation and other policies including reference
pricing for the molecule, generic substitution in pharma-
cies and encouraging INN prescribing can reduce the
prescribing and dispensing of originators.43–46 Multiple
demand-side policy measures to enhance the prescrip-
tion of generics in a class versus patented products have
also reduced costs while volumes have increased.37 39 47 48
Korean drug policy does not use a reference pricing
system, and Korean physicians can prescribe only by a
speciﬁc brand name, not by a non-proprietary name.
This is different from the practice in a number of
European countries.
The effects of the new guidelines on drug utilisation
were higher among Medical aid beneﬁciaries than among
health insurance participants. In ﬁgure 3, Medical aid
beneﬁciaries had higher daily drug utilisation than health
insurance beneﬁciaries, but this became similar after the
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guidelines were introduced. Therefore, the effect on drug
utilisation for Medical aid beneﬁciaries was larger because
they used more antihypertensive drugs than recom-
mended by the new guideline. The copayment decreased
because of the drug price reduction, and a previous study
reported that Medical aid beneﬁciaries used more drugs
than health insurance beneﬁciaries.49 Therefore, the
effect on health inequality was low.
This study has several limitations. The follow-up
periods were short from the date when the guidelines
were implemented. Patients with secondary hyperten-
sion were excluded from this study. Thus, these results
do not represent all patients with hypertension in Korea.
As the unit of analysis was aggregated monthly per
person, hospital characteristics were not captured in the
analysis. There may remain hospital effects in drug util-
isation variables. There was no control in this study. The
effects of the guidelines may be combined by the drug
price reduction. Since we conducted the segmented
regression by period, the results were still similar. The
health outcomes were not evaluated in this study.
Further study should identify the effects on health
outcomes.
CONCLUSION
The policies saved money. The guidelines, which were
issued as a prescribing restriction, were more effective
and resulted in fewer unintended impacts than drug
price reduction, which was a direct price control policy.
The drug price reduction had strong effects at the
implementation of the new policy, but the effects of
restrictions on the prescription of drugs became more
evident over time. Policymakers should consider the
unintended impacts, such as increasing daily drug util-
isation and the number of drugs and the comprehensive
effects when introducing new policies.
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Table 5 Marginal effects from results of segmented regression analysis
Group
Drug price reduction
in December 2012
(compared to March
2012)
New guidelines
in October 2013
(compared to
January 2013)
Both policies in
December 2013
(compared to March 2012)
Daily drug utilisation All +0.0153 −0.0307* −0.0050
Health insurance +0.0157 −0.0306 −0.0043
Medical aid +0.0023 −0.0377* −0.0394
Average number of drugs
per month
All −0.0121* −0.1612* −0.1883*
Health insurance −0.0119* −0.1621* −0.1886*
Medical aid −0.0224 −0.1484* −0.1972
Per cent of original
drugs (%)
All +0.0947 +0.2197 +0.5402
Health insurance +0.1483 +0.1124 +0.5267
Medical aid −0.4887 +1.6364 +0.9739
Drug overutilisation
(probability)
All +0.00358 −0.00206 +0.00544
Health insurance +0.00350 −0.00206 +0.00522
Medical aid +0.00240 −0.02158 −0.01912
Prohibited combination
(probability)
All +0.00768 −0.00719 +0.00952
Health insurance +0.00765 −0.00704 +0.00979
Medical aid −0.00795 −0.00652 −0.04079
Antihypertensive drug costs
(USD)
All −1.5137* −2.1272* −4.2217*
Health insurance −1.5304* −2.1128* −4.2312*
Medical aid −1.2514 −2.3844 −4.0456
Antihypertensive drug cost
per prescribing day (USD)
All −0.0442 −0.0732* −0.1346
Health insurance −0.0450 −0.0731* −0.1363
Medical aid −0.0354 −0.0791 −0.1201
*Variables-related policies and times are significant (p<0.05).
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